Almeda Ventures

Almeda Ventures Overview

Almeda Ventures is a HealthTech focused public R&D partnership. It invests on a global basis while focusing on Medical devices, Digital health and Bio-convergence. Almeda Ventures help its portfolio companies to thrive using its teams deep expertise, diverse background and extensive network with investors, strategics and medical centers worldwide. Almeda Ventures seeks for exceptional teams with innovative solutions addressing major unmet needs with a proven clinical concept and a proven business model. Almeda Ventures drives medical device and digital health companies for success by utilizing its extensive network and proven track record. The partnership plans to invest in Israel and overseas companies with research and development projects in digital health and medical devices, with the aim of building a varied portfolio with exits expected after 1-5 years. The focus will be on companies at the clinical stage after proof of concept and human trials, with the capital invested being earmarked for trials required in order to obtain approval from the US Food and Drug Administration and to start sales.

Latest News

Dec 6, 2021 · www.globes.co.il

growth-positive

אלמדה חתמה על שיתוף פעולה עם חברת המסחור של כללית

Israeli biomed partnership אלמדה ונצרס has signed a cooperation agreement with the trading company of Clalit Health Services, Mor Yishum. The partnership will allow אלמדה ונצרס, which invests in digital health and medical equipment, to utilize the information accumulated by Clalit on its way to developing its products, consult with its experts, and test its products as pilots and clinical trials in Clalit. The company raised 70 million shekels in October 2020 and is currently traded at a value of 64 million shekels.

PartnersInvestment

Oct 27, 2021 · www.sponser.co.il

growth-positive

אלמדה ונצרס גייסה 27 מיליון ש"ח בהנפקת זכויות

Healthcare investment partnership Almeda Ventures has completed a fundraising round, raising 27 million shekels ($8.2 million) through the issuance of rights. The funds will be used to invest in new companies and continue investments in the existing portfolio. The majority of shareholders participated in the fundraising, including general partners Zachi Sultan, Dr. Irit Yaniv, Amir Blatt, and Arie Jacobson, as well as anchor investors such as Phoenix Group and Company Trust Geneva. Almeda Ventures has already made investments in eight promising healthcare and medical device companies, alongside investors like Johnson & Johnson Innovation, IQVIA, and HCA. The partnerships management team will continue to support and promote the portfolio companies.

Investment

Aug 24, 2021 · chiportal.co.il

growth-positive

אלמדה ונצ'רס הובילה עם J&J סבב השקעה של 13 מ' דולר ב'פלקס דקס' - Chiportal

FlexDex, a company specializing in the development, manufacturing, marketing, and distribution of advanced semi-robotic surgical tools, has secured an investment of $13 million. The funding round was led by Almeda Ventures and Johnson & Johnson Innovation – JJDC. The funds will be used to develop the next generation of the product, which has already been used in thousands of minimally invasive surgeries in the US and other countries. The global market for minimally invasive surgeries is expected to grow to $58.2 billion by 2024.

Investment

Apr 27, 2021 · hotstocks.co.il

growth-positive

זרקור על שותפות אלמדה: שש חברות מבטיחות שבהן הושקעו 11 מיליון דולר - וזה לא הולך להיעצר - hot stocks

אלמדה, a company that invests in digital health and medical equipment companies, has invested in six companies so far, with a total investment of $11.25 million. The company, which was listed on the Tel Aviv Stock Exchange, has raised about $19.2 million net after issuance expenses. The companys portfolio includes BioProtect, Augmedics, and Virility. The company also plans to acquire a portfolio of companies from the Anatomy Fund from Clal Biotechnology.

InvestmentAcquisition

Mar 18, 2021 · en.globes.co.il

growth-positive

Clal Biotech to form $100m SPAC

Clal Biotechnology Industries is forming a SPAC and spinning off its Anatomy medical technology funds. The company also declared a dividend and announced a share buyback program. The plan for the SPAC is to raise $100 million to invest in a company valued between $500 million and $1 billion. The company is looking for a pharmaceutical or digital health company connected to pharmaceuticals in Israel. Clal Biotech is also selling its Anatomy funds to Almeda Ventures in exchange for shares. The partners in the Anatomy funds will receive participation units in Almeda Ventures.

InvestmentPartners

Team Members

4

Web & Social Links

Locations

Azrieli Center, Derech Menachem Begin, Tel Aviv-Yafo, Israel

Photos & Videos

No files yet

Almeda Ventures Internal

Recent Updates

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info